UZMA HAQUE M.D.
Prescription History 1104875137
Internal Medicine - Rheumatology in Baltimore, MD


Quality Rating: 74.39 out of 100 score

NPI Status: Active since May 08, 2006

Contact Information

4940 EASTERN AVENUE
BALTIMORE, MD
ZIP 21287
Phone: (410) 550-2400

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for UZMA HAQUE M.D., an active Rheumatology specialist practicing in Baltimore, MD. Our medical registry currently tracks 15 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 777 documented patient claims. Among these therapy options, the most frequently utilized medication is Methotrexate, which accounts for 201 claims alone.


Duloxetine Hcl

Generic Formulation: Duloxetine HclSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 12
30-Day Fills 24.0
Days Supply 720
MD State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills70.6
Peer Average Days Supply2,086
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $964.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.35

State Avg Cost Per Claim

$53.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

Therapeutic Applications

Duloxetine is used to treat depression and anxiety. In addition, duloxetine is used to help relieve nerve pain (peripheral neuropathy) in people with diabetes or ongoing pain due to medical conditions such as arthritis, chronic back pain, or fibromyalgia (a condition that causes widespread pain). Duloxetine may improve your mood, sleep, appetite, and energy level, and decrease nervousness. It can also decrease pain due to certain medical conditions. Duloxetine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). This medication works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Enbrel

Generic Formulation: EtanerceptSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 13
30-Day Fills 14.8
Days Supply 420
MD State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills19.9
Peer Average Days Supply564
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,561.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,658.54

State Avg Cost Per Claim

$7,686.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

Enbrel Sureclick

Generic Formulation: EtanerceptSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 42
30-Day Fills 49.5
Days Supply 1,427
MD State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply945
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $349,531.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,322.18

State Avg Cost Per Claim

$7,828.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

Folic Acid

Generic Formulation: Folic AcidSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 46
30-Day Fills 100.0
Days Supply 2,962
MD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills43.2
Peer Average Days Supply1,279
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 130.0% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $133.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.91

State Avg Cost Per Claim

$5.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia.

Therapeutic Applications

Folic acid is the man-made form of folate. Folate is a B-vitamin naturally found in some foods. It is needed to form healthy cells, especially red blood cells. Folic acid supplements may come in different forms (such as L-methylfolate, levomefolate, methyltetrahydrofolate). They are used to treat or prevent low folate levels. Low folate levels can lead to certain types of anemia. Conditions that can cause low folate levels include poor diet, pregnancy, alcoholism, liver disease, certain stomach/intestinal problems, kidney dialysis, among others. Women of childbearing age should receive adequate amounts of folic acid either through their diet or supplements to prevent infant spinal cord birth defects.

Gabapentin

Generic Formulation: GabapentinSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 26
30-Day Fills 31.0
Days Supply 898
MD State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills104.6
Peer Average Days Supply3,047
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $94.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.62

State Avg Cost Per Claim

$21.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Humira

Generic Formulation: AdalimumabSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 379
MD State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills14.6
Peer Average Days Supply414
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $92,831.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,630.79

State Avg Cost Per Claim

$7,160.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Humira(Cf)

Generic Formulation: AdalimumabSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.3
Days Supply 590
MD State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.3
Peer Average Days Supply518
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $169,122.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,456.11

State Avg Cost Per Claim

$7,893.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Humira(Cf) Pen

Generic Formulation: AdalimumabSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 27
30-Day Fills 35.2
Days Supply 996
MD State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply771
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $298,814.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,067.20

State Avg Cost Per Claim

$8,865.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Hydroxychloroquine Sulfate

Generic Formulation: Hydroxychloroquine SulfateSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 83
30-Day Fills 244.7
Days Supply 7,340
MD State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills146.8
Peer Average Days Supply4,369
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,339.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$64.33

State Avg Cost Per Claim

$72.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Therapeutic Applications

Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits.

Leflunomide

Generic Formulation: LeflunomideSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 83
30-Day Fills 217.1
Days Supply 6,364
MD State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills84.8
Peer Average Days Supply2,503
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 112.8% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,447.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.68

State Avg Cost Per Claim

$107.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Therapeutic Applications

This medication is used to treat rheumatoid arthritis, a condition in which the body's defense system (immune system) fails to recognize the body as itself and attacks the healthy tissues around the joints. Leflunomide helps to reduce the joint damage/pain/swelling and helps you to move better. It works by weakening your immune system and decreasing swelling (inflammation).

Methotrexate

Generic Formulation: Methotrexate SodiumSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 201
30-Day Fills 501.8
Days Supply 14,898
MD State Average Benchmarks
Peer Average Claims80.0
Peer Average 30-Day Fills173.7
Peer Average Days Supply5,134
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 151.3% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,317.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.28

State Avg Cost Per Claim

$44.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Therapeutic Applications

Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma) or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.

Prednisone

Generic Formulation: PrednisoneSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 128
30-Day Fills 255.6
Days Supply 7,314
MD State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills50.6
Peer Average Days Supply992
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 228.2% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,277.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.98

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Simponi

Generic Formulation: GolimumabSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 18
30-Day Fills 24.0
Days Supply 692
MD State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills17.2
Peer Average Days Supply501
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140,495.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,805.32

State Avg Cost Per Claim

$6,751.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, and ankylosing spondylitis). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage. By reducing joint swelling, the medication helps to reduce further joint damage and preserve joint function. Depending on the type of arthritis that is being treated, this drug may be used alone or in combination with another drug called methotrexate. This medication is also used to treat a certain bowel condition (ulcerative colitis). It is used to help lessen symptoms of moderate to severe ulcerative colitis (such as abdominal pain/cramping, diarrhea, bloody stools).

Sulfasalazine

Generic Formulation: SulfasalazineSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 49
30-Day Fills 102.3
Days Supply 3,058
MD State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills51.6
Peer Average Days Supply1,521
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 88.5% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,677.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.23

State Avg Cost Per Claim

$31.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)

Therapeutic Applications

Sulfasalazine is used to treat a certain type of bowel disease called ulcerative colitis. This medication does not cure this condition, but it helps decrease symptoms such as fever, stomach pain, diarrhea, and rectal bleeding. After an attack is treated, sulfasalazine is also used to increase the amount of time between attacks. This medication works by reducing irritation and swelling in the large intestines. In addition, delayed-release tablets of sulfasalazine are used to treat rheumatoid arthritis. Sulfasalazine helps to reduce joint pain, swelling, and stiffness. Early treatment of rheumatoid arthritis with sulfasalazine helps to reduce/prevent further joint damage so you can do more of your normal daily activities. This medication is used with other drugs, rest, and physical therapy in patients who have not responded to other medications (salicylates, nonsteroidal anti-inflammatory drugs-NSAIDs).

Xeljanz

Generic Formulation: Tofacitinib CitrateSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
MD State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply860
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $79,207.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,280.48

State Avg Cost Per Claim

$4,690.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis-pcJIA). It helps to decrease pain/tenderness/swelling in the joints. Tofacitinib is also used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like UZMA HAQUE M.D. provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Rheumatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.